<DOC>
	<DOCNO>NCT00902356</DOCNO>
	<brief_summary>The primary objective study determine safety tolerability AMG 167 follow single dose subcutaneous ( SC ) intravenous ( IV ) administration healthy men postmenopausal woman .</brief_summary>
	<brief_title>A First-in-human Study Evaluating AMG 167 Healthy Men Postmenopausal Women</brief_title>
	<detailed_description />
	<mesh_term>Bone Diseases , Metabolic</mesh_term>
	<criteria>Healthy male females 45 65 year age Postmenopausal female define 12 continuous month spontaneous amenorrhea confirm serum folliclestimulating hormone ( FSH ) result &gt; 40mIU/mL , least 6 week postsurgical bilateral oophorectomy ( without hysterectomy ) Men must agree use highly effective method contraception ; male must agree donate sperm entire study 7 month end treatment Weight ≤ 98 kg ( 216 lb ) and/or height ≤ 196 cm ( 77 ) Has history evidence clinically significant disorder , condition disease would pose risk subject safety interfere study evaluation , procedures completion Negative urine screen potential drug abuse screen admission , unless medication prescribe physician Healthy male partner pregnant time screen ; healthy male partner plan become pregnant study Osteoporosis , define BMD tscores lumbar spine ( L1L4 ) total evaluable vertebra ; femoral neck ≤ 2.5 Diagnosed condition affect bone metabolism Diagnosis clot factor deficiency history bleed coagulation disorder ( include history heparin warfarin administration ) Subjects few 2 evaluable vertebra ; metal hip bilaterally would allow least one evaluable hip ; metal forearm bilaterally would allow least one evaluable forearm Abnormal international normalize ratio partial thromboplastin time Administration follow medication within 6 month study drug administration : Hormone replacement therapy [ Infrequent use estrogen vaginal cream ( &lt; 3 time per week ) allow . ] Calcitonin Parathyroid hormone ( derivative ) Supplemental Vitamin D &gt; 1,000 IU/day Glucocorticosteroids ( inhaled topical corticosteroid administer 2 week enrollment date allow ) Anabolic steroid Calcitriol , available analogue Administration follow medication within 12 month study drug administration : Bisphosphonates Fluoride osteoporosis Administration herbal medication within 2 week 5 halflives ( whichever longer ) study drug administration Greatly differ level physical activity constant level intense physical exercise 6 month study drug administration Known alcohol abuse use illicit drug within 12 month admission Unwilling unable limit alcohol consumption throughout course study Known sensitivity mammalianderived drug preparation Known hepatitis B surface antigen , hepatitis C virus , human immunodeficiency virus positive , know diagnosis acquire immunodeficiency syndrome An unstable medical condition , define hospitalize within 28 day day 1 , major surgery within 6 month day 1 , otherwise unstable judgment investigator Has clinically significant abnormality screen physical examination , ECG , laboratory evaluation Unavailable followup assessment concern subject 's compliance protocol procedures Any condition might reduce chance obtain data require protocol might compromise ability give truly informed consent Has participate another clinical study within 4 week screen within 5 time halflife investigational agent clinical study , know Has donate lose 400 mL blood plasma within 8 week study drug administration Previous exposure AMG 785</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Amgen</keyword>
	<keyword>Phase 1</keyword>
	<keyword>First Human</keyword>
	<keyword>Postmenopausal</keyword>
</DOC>